Marc Espié - Concepedia

Author

Marc Espié

Hôpital Saint-Louis ORCID

Also Known As

Espie, Marc, Espié M., Espié, Marc, M Espie, M Espié, M Espié, M. ESPIE, M. Espie, M. Espié, M. Espié

377

Publications

10.1K

Citations

H-Index

Concepts

All Affiliations

Hôpital Saint-Louis Université Paris Cité Inserm Assistance Publique – Hôpitaux de Paris Institut Curie

About

Marc Espié is an author at Hôpital Saint-Louis specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	55	5.1K
2	Health Sciences	15	18	1.9K
3	Engineering	4	4	623
4	Natural Sciences	1	1	16
5	Nursing	1	1	18

Marc Espié

102

Publications

8.2K

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, The Lancet Oncology First-line TherapyBreast OncologyMedicinePharmacologyClinical Trials	2017	463
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer David Groheux, Sylvie Giacchetti, Jean‐Luc Moretti, European Journal of Nuclear Medicine and Molecular Imaging Breast OncologyEngineeringHigh 18F-fdg UptakeMedicineMolecular Imaging	2010	391
Phase I study of oxaliplatin in patients with advanced cancer Jean Marc Extra, Marc Espié, Fabien Calvo, Cancer Chemotherapy and Pharmacology Advanced CancerMedicineCancer ManagementCancer TreatmentOncology	1990	338
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial X. Pivot, Gilles Romieu, Marc Debled, The Lancet Oncology Breast OncologyMedicineRandomised Phase 3Clinical TrialsBreast Cancer	2013	337
Molecular Profiling of Inflammatory Breast Cancer Ivan Bièche, Florence Lerebours, Sengül Tozlu, Clinical Cancer Research	2004	254
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy M. Marty, Marc Espié, Alain Monnier, Annals of Oncology Breast OncologyOncologyMedicineAnthracycline-based ChemotherapyBreast Cancer	2006	192
NF-kappa B genes have a major role in Inflammatory Breast Cancer Florence Lerebours, Sophie Vacher, Catherine Andrieu, BMC Cancer	2008	180
Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen Philippe Bertheau, Elisabeth Turpin, David S. Rickman, PLoS Medicine	2007	173
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. R. Charles Coombes, Judith M. Bliss, J. Wils, Journal of Clinical Oncology	1996	170

Page 1